Companion Diagnostics Market by Product (Assays, Kits, & Reagents, Instruments, Software), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious), Drug Class (MAB, Cell & Gene Therapy) - Global Forecast to 2031

1 INTRODUCTION 40 1.1 STUDY OBJECTIVES 40 1.2 MARKET DEFINITION 40 1.3 STUDY SCOPE 41 1.3.1 MARKETS COVERED & REGIONAL SCOPE 41 1.3.2 INCLUSIONS & EXCLUSIONS 42 1.3.3 YEARS CONSIDERED 42 1.3.4 CURRENCY CONSIDERED 43 1.4 STAKEHOLDERS 43 1.5 SUMMARY OF CHANGES 43 2 EXECUTIVE SUMMARY 45 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 45 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 46 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 47 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 48 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 49 3 PREMIUM INSIGHTS 50 3.1 COMPANION DIAGNOSTICS MARKET OVERVIEW 50 3.2 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031 50 3.3 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031 51 3.4 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2026 VS. 2031 51 3.5 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2026 VS. 2031 52 3.6 COMPANION DIAGNOSTICS MARKET, BY DRUG ASSOCIATED WITH CDX, 2026 VS. 2031 52 3.7 COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2026 VS. 2031 53 3.8 COMPANION DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53 4 MARKET OVERVIEW 54 4.1 INTRODUCTION 54 4.2 MARKET DYNAMICS 55 4.2.1 DRIVERS 55 4.2.1.1 Increasing adoption of precision medicine and targeted therapies 55 4.2.1.2 Growing investments in genomics, molecular diagnostics, and biomarker discovery 56 4.2.1.3 Expanding pharmaceutical-diagnostic co-development partnerships 57 4.2.2 RESTRAINTS 58 4.2.2.1 High development, clinical validation, and regulatory approval costs 58   4.2.3 OPPORTUNITIES 59 4.2.3.1 Expansion of liquid biopsy and non-invasive companion diagnostics 59 4.2.3.2 AI-driven biomarker interpretation and digital pathology integration 59 4.2.4 CHALLENGES 60 4.2.4.1 Regulatory complexity associated with simultaneous drug-diagnostic approvals 60 4.3 UNMET NEEDS & WHITE SPACES 61 4.3.1 UNMET NEEDS IN COMPANION DIAGNOSTICS MARKET 61 4.3.2 WHITE SPACE OPPORTUNITIES 63 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 64 4.4.1 INTERCONNECTED MARKETS 64 4.4.2 CROSS-SECTOR OPPORTUNITIES 65 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 66 4.5.1 KEY MOVES & STRATEGIC FOCUS 67 5 INDUSTRY TRENDS 68 5.1 PORTER’S FIVE FORCES ANALYSIS 68 5.1.1 BARGAINING POWER OF SUPPLIERS 69 5.1.2 BARGAINING POWER OF BUYERS 69 5.1.3 THREAT OF NEW ENTRANTS 69 5.1.4 THREAT OF SUBSTITUTES 70 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 70 5.2 MACROECONOMIC OUTLOOK 70 5.2.1 INTRODUCTION 70 5.2.2 GDP TRENDS & FORECAST 70 5.2.3 TRENDS IN GLOBAL COMPANION DIAGNOSTICS INDUSTRY 73 5.3 SUPPLY CHAIN ANALYSIS 74 5.4 VALUE CHAIN ANALYSIS 76 5.5 ECOSYSTEM ANALYSIS 78 5.6 PRICING ANALYSIS 80 5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2024–2026 80 5.6.2 AVERAGE SELLING PRICE TREND, BY REGION, 2024–2026 81 5.6.3 AVERAGE SELLING PRICE TREND, BY TECHNOLOGY TYPE, 2024–2026 82 5.7 TRADE ANALYSIS 83 5.7.1 IMPORT SCENARIO (HS CODE 3822) 83 5.7.2 EXPORT SCENARIO (HS CODE 3822) 83 5.8 KEY CONFERENCES & EVENTS, 2026–2027 84 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 85 5.10 INVESTMENT & FUNDING SCENARIO 86   5.11 IMPACT OF US TARIFFS—COMPANION DIAGNOSTICS MARKET 86 5.11.1 INTRODUCTION 86 5.11.2 KEY TARIFF RATES 87 5.11.3 PRICE IMPACT ANALYSIS 87 5.11.4 IMPACT ON COUNTRIES/REGIONS 88 5.11.4.1 North America 88 5.11.4.2 Europe 88 5.11.4.3 Asia Pacific 89 5.11.5 IMPACT ON END-USE INDUSTRIES 89 5.11.5.1 Hospital and cancer centers 89 5.11.5.2 Pharmaceutical and biopharmaceutical companies 90 5.11.5.3 Other end users 90 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 91 6.1 KEY EMERGING TECHNOLOGIES 91 6.1.1 NEXT-GENERATION SEQUENCING (NGS)-BASED COMPREHENSIVE GENOMIC PROFILING 91 6.1.2 LIQUID BIOPSY (CFDNA/CTDNA TESTING) 91 6.2 COMPLEMENTARY TECHNOLOGIES 92 6.2.1 BIOINFORMATICS & AI-DRIVEN CLINICAL INTERPRETATION 92 6.2.2 MULTIPLEX PCR/QPCR PLATFORMS 92 6.3 ADJACENT TECHNOLOGIES 93 6.3.1 DIGITAL PATHOLOGY & AI-BASED IMAGING 93 6.4 TECHNOLOGY/PRODUCT ROADMAP 93 6.5 PATENT ANALYSIS 95 6.5.1 LIST OF MAJOR PATENTS 96 6.6 FUTURE APPLICATIONS 96 6.7 IMPACT OF AI/GENERATIVE AI ON COMPANION DIAGNOSTICS MARKET 97 6.7.1 INTRODUCTION 97 6.7.2 TOP USE CASES & MARKET POTENTIAL 98 6.7.3 KEY COMPANIES IMPLEMENTING AI 99 6.7.4 FUTURE OF AI 99 7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES 100 7.1 REGIONAL REGULATIONS & COMPLIANCE 100 7.1.1 REGULATORY ANALYSIS 100 7.1.1.1 North America 100 7.1.1.1.1 US 100 7.1.1.1.2 Canada 100   7.1.1.2 Europe 100 7.1.1.2.1 Germany 101 7.1.1.2.2 UK 102 7.1.1.2.3 France 102 7.1.1.2.4 Italy 102 7.1.1.3 Asia Pacific 102 7.1.1.3.1 China 102 7.1.1.3.2 Japan 103 7.1.1.3.3 India 103 7.1.1.3.4 Australia 103 7.1.1.4 Latin America 104 7.1.1.4.1 Brazil 104 7.1.1.4.2 Mexico 105 7.1.1.5 Middle East 105 7.1.1.5.1 Africa 105 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 7.2 SUSTAINABILITY INITIATIVES 107 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES 107 7.2.1.1 Eco-friendly initiatives 108 7.2.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 108 8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 110 8.1 DECISION-MAKING PROCESS 110 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 110 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 110 8.2.2 BUYING CRITERIA 111 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 112 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 113 8.5 MARKET PROFITABILITY 114 8.5.1 REVENUE POTENTIAL 115 8.5.2 COST DYNAMICS 115 9 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE 116 9.1 INTRODUCTION 117 9.2 ASSAYS, KITS, AND REAGENTS 117 9.2.1 INCREASING ROUTINE USE OF BIOMARKER-BASED TESTING FOR TARGETED THERAPY AND IMMUNOTHERAPY SELECTION 117 9.3 INSTRUMENTS/SYSTEMS 122 9.3.1 RISING ADOPTION OF AUTOMATED MOLECULAR, PATHOLOGY, AND NGS PLATFORMS TO SUPPORT STANDARDIZED AND SCALABLE CDX TESTING 122   9.4 SOFTWARE & SERVICES 126 9.4.1 INCREASING DEMAND FOR HIGH-VALUE NGS INTERPRETATION, LIQUID BIOPSY SERVICES, PHARMA CDX CO-DEVELOPMENT, AND CLINICALLY ACTIONABLE REPORTING 126 10 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE 131 10.1 INTRODUCTION 132 10.2 TISSUE SAMPLES 132 10.2.1 CONTINUED DOMINANCE OF TISSUE-BASED BIOMARKER TESTING IN ONCOLOGY TREATMENT SELECTION 132 10.3 BLOOD SAMPLES 136 10.3.1 RAPID ADOPTION OF LIQUID BIOPSY AND CIRCULATING TUMOR DNA-BASED COMPANION DIAGNOSTICS TO DRIVE MARKET 136 10.4 OTHER SAMPLE TYPES 140 11 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY 144 11.1 INTRODUCTION 145 11.2 POLYMERASE CHAIN REACTION 146 11.2.1 PREFERENCE FOR COST-EFFECTIVE, CLINICALLY ESTABLISHED SINGLE-GENE/HOTSPOT MUTATION TESTING DRIVES MARKET 146 11.3 IN SITU HYBRIDIZATION 150 11.3.1 NEED FOR TISSUE-BASED DETECTION OF GENE AMPLIFICATION, REARRANGEMENTS, AND EXPRESSION-LINKED THERAPY SELECTION DRIVE MARKET 150 11.4 NEXT-GENERATION SEQUENCING 154 11.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET 154 11.5 IMMUNOHISTOCHEMISTRY 158 11.5.1 STRONG USE OF TISSUE-BASED PROTEIN-EXPRESSION TESTING FOR IMMUNO-ONCOLOGY AND TARGETED THERAPY SELECTION 158 11.6 OTHER TECHNOLOGIES 162 12 COMPANION DIAGNOSTICS MARKET, BY INDICATION 166 12.1 INTRODUCTION 167 12.2 CANCER 167 12.2.1 LUNG CANCER 172 12.2.1.1 Growing demand for effective therapeutic drugs to increase CDx adoption 172 12.2.2 BREAST CANCER 175 12.2.2.1 Wide prevalence of breast cancer among women contributes to the large market size of the segment 175 12.2.3 LEUKEMIA & LYMPHOMA 179 12.2.3.1 Precision profiling of targeted alterations in hematologic malignancies 179   12.2.4 COLORECTAL CANCER 182 12.2.4.1 Integration of biomarker testing for targeted and immunotherapy selection 182 12.2.5 MELANOMA 185 12.2.5.1 High immunotherapy and targeted therapy use based on molecular status 185 12.2.6 OTHER CANCERS 188 12.3 NEUROLOGICAL DISEASES 191 12.3.1 RISING BURDEN OF NEURODEGENERATIVE DISEASES TO DRIVE MARKET 191 12.4 CARDIOVASCULAR DISEASES 194 12.4.1 RISING GLOBAL INCIDENCE OF CARDIOVASCULAR PATIENTS TO EXPEDITE GROWTH 194 12.5 INFECTIOUS DISEASES 197 12.5.1 INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL SEGMENT GROWTH 197 12.6 OTHER INDICATIONS 200 13 COMPANION DIAGNOSTICS MARKET VOLUME ANALYSIS FOR CANCER, BY REGION (NUMBER OF TESTS) 204 14 COMPANION DIAGNOSTICS MARKET, BY APPLICATION 205 14.1 INTRODUCTION 206 14.2 CLINICAL DIAGNOSTICS 206 14.2.1 INCREASING USE OF CDX TESTING FOR REAL-TIME THERAPY SELECTION IN ONCOLOGY AND PRECISION MEDICINE 206 14.3 RESEARCH USE 209 14.3.1 RISING BIOMARKER DISCOVERY AND PHARMA-LED DRUG–DIAGNOSTIC CO-DEVELOPMENT PROGRAMS 209 15 COMPANION DIAGNOSTICS MARKET, BY END USER 213 15.1 INTRODUCTION 214 15.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 214 15.2.1 RISING PHARMA-LED DRUG–DIAGNOSTIC CO-DEVELOPMENT FOR TARGETED THERAPIES AND IMMUNOTHERAPIES DRIVES MARKET 214 15.3 REFERENCE LABORATORIES 218 15.3.1 INCREASING DEMAND FOR OUTSOURCED HIGH-COMPLEXITY MOLECULAR AND GENOMIC CDX TESTING 218 15.4 CONTRACT RESEARCH ORGANIZATIONS 221 15.4.1 INCREASING USE OF BIOMARKER-DRIVEN CLINICAL TRIALS AND CDX-ENABLED DRUG DEVELOPMENT PROGRAMS 221 15.5 OTHER END USERS 224   16 COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH CDX 228 16.1 INTRODUCTION 229 16.2 MONOCLONAL ANTIBODIES 229 16.2.1 RISING USE OF BIOMARKER-GUIDED MONOCLONAL ANTIBODY THERAPIES IN ONCOLOGY AND IMMUNO-ONCOLOGY 229 16.3 CELL & GENE THERAPY 232 16.3.1 INCREASING NEED FOR GENETIC, ANTIGEN, AND PATIENT-ELIGIBILITY TESTING IN ADVANCED PERSONALIZED THERAPIES 232 17 COMPANION DIAGNOSTICS MARKET, BY REGION 236 17.1 INTRODUCTION 237 17.2 NORTH AMERICA 237 17.2.1 US 243 17.2.1.1 Presence of advanced healthcare infrastructure to augment growth 243 17.2.2 CANADA 246 17.2.2.1 Expanding public oncology testing infrastructure and growing biomarker-based cancer care 246 17.3 EUROPE 250 17.3.1 GERMANY 253 17.3.1.1 Advanced molecular pathology infrastructure and strong oncology testing adoption 253 17.3.2 UK 257 17.3.2.1 NHS-led genomic medicine infrastructure and national test directory-based access 257 17.3.3 FRANCE 260 17.3.3.1 National cancer programs and structured molecular oncology networks 260 17.3.4 ITALY 264 17.3.4.1 Expanding molecular oncology adoption across regional cancer centers 264 17.3.5 SWITZERLAND 268 17.3.5.1 High-value precision medicine environment and strong pharma-diagnostics presence 268 17.3.6 SPAIN 271 17.3.6.1 Increasing adoption of biomarker-guided oncology across public hospital networks 271 17.3.7 REST OF EUROPE 275 17.4 ASIA PACIFIC 279 17.4.1 CHINA 284 17.4.1.1 Large oncology patient pool and rapid expansion of domestic precision medicine infrastructure 284 17.4.2 JAPAN 287 17.4.2.1 Universal healthcare reimbursement policy to foster growth 287 17.4.3 INDIA 291 17.4.3.1 Increased private and public investments to bolster growth 291 17.4.4 SOUTH KOREA 294 17.4.4.1 Advanced healthcare infrastructure and strong adoption of precision oncology technologies 294 17.4.5 AUSTRALIA 297 17.4.5.1 Strong oncology care infrastructure and high biomarker testing need in melanoma and solid tumors 297 17.4.6 REST OF ASIA PACIFIC 300 17.5 LATIN AMERICA 304 17.5.1 BRAZIL 307 17.5.1.1 Largest oncology patient pool in Latin America and growing adoption of precision oncology in private healthcare 307 17.5.2 MEXICO 310 17.5.2.1 Expanding oncology care networks and increasing use of biomarker testing in urban cancer centers 310 17.5.3 REST OF LATIN AMERICA 313 17.6 MIDDLE EAST & AFRICA 316 17.6.1 GCC COUNTRIES 320 17.6.1.1 Growing public healthcare funding to drive market 320 17.6.2 REST OF MIDDLE EAST & AFRICA 323 18 COMPETITIVE LANDSCAPE 327 18.1 INTRODUCTION 327 18.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 327 18.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN COMPANION DIAGNOSTICS MARKET 327 18.3 REVENUE ANALYSIS, 2023–2025 329 18.4 MARKET SHARE ANALYSIS, 2025 330 18.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 330 18.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 331 18.5.1 STARS 331 18.5.2 EMERGING LEADERS 331 18.5.3 PERVASIVE PLAYERS 331 18.5.4 PARTICIPANTS 332 18.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 333 18.5.5.1 Company footprint 333 18.5.5.2 Region footprint 333 18.5.5.3 Product & service footprint 334 18.5.5.4 Indication footprint 335 18.5.5.5 Technology footprint 335   18.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 336 18.6.1 PROGRESSIVE COMPANIES 336 18.6.2 RESPONSIVE COMPANIES 336 18.6.3 DYNAMIC COMPANIES 336 18.6.4 STARTING BLOCKS 336 18.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 337 18.6.5.1 Detailed list of key startups/SMEs 337 18.6.5.2 Competitive benchmarking of startups/SMEs 338 18.7 COMPANY VALUATION & FINANCIAL METRICS 339 18.7.1 FINANCIAL METRICS 339 18.7.2 COMPANY VALUATION 339 18.8 BRAND/PRODUCT COMPARISON 340 18.9 COMPETITIVE SCENARIO 341 18.9.1 PRODUCT LAUNCHES & APPROVALS 341 18.9.2 DEALS 342 18.9.3 EXPANSIONS 343 18.9.4 OTHER DEVELOPMENTS 343 19 COMPANY PROFILES 344 19.1 KEY PLAYERS 344 19.1.1 F. HOFFMANN-LA ROCHE LTD. 344 19.1.1.1 Business overview 344 19.1.1.2 Products/Services/Solutions offered 345 19.1.1.3 Recent developments 347 19.1.1.3.1 Product launches & approvals 347 19.1.1.3.2 Deals 349 19.1.1.3.3 Expansions 349 19.1.1.4 MnM view 349 19.1.1.4.1 Key strengths 349 19.1.1.4.2 Strategic choices 350 19.1.1.4.3 Weaknesses & competitive threats 350 19.1.2 AGILENT TECHNOLOGIES, INC 351 19.1.2.1 Business overview 351 19.1.2.2 Products/Services/Solutions offered 352 19.1.2.3 Recent developments 353 19.1.2.3.1 Product launches & approvals 353 19.1.2.3.2 Deals 354 19.1.2.4 MnM view 354 19.1.2.4.1 Key strengths 354 19.1.2.4.2 Strategic choices 355 19.1.2.4.3 Weaknesses & competitive threats 355   19.1.3 QIAGEN 356 19.1.3.1 Business overview 356 19.1.3.2 Products/Services/Solutions offered 357 19.1.3.3 Recent developments 358 19.1.3.3.1 Product launches & approvals 358 19.1.3.3.2 Deals 359 19.1.3.3.3 Expansions 359 19.1.3.4 MnM view 360 19.1.3.4.1 Key strengths 360 19.1.3.4.2 Strategic choices 360 19.1.3.4.3 Weaknesses & competitive threats 360 19.1.4 THERMO FISHER SCIENTIFIC INC. 361 19.1.4.1 Business overview 361 19.1.4.2 Products/Services/Solutions offered 362 19.1.4.3 Recent developments 364 19.1.4.3.1 Product launches 364 19.1.4.3.2 Deals 364 19.1.4.4 MnM view 365 19.1.4.4.1 Key strengths 365 19.1.4.4.2 Strategic choices 365 19.1.4.4.3 Weaknesses & competitive threats 365 19.1.5 ABBOTT 366 19.1.5.1 Business overview 366 19.1.5.2 Products/Services/Solutions offered 367 19.1.5.3 Recent developments 368 19.1.5.3.1 Product approvals 368 19.1.5.3.2 Deals 369 19.1.5.4 MnM view 369 19.1.5.4.1 Key strengths 369 19.1.5.4.2 Strategic choices 369 19.1.5.4.3 Weaknesses & competitive threats 370 19.1.6 DANAHER 371 19.1.6.1 Business overview 371 19.1.6.2 Products/Services/Solutions offered 372 19.1.6.3 Recent developments 373 19.1.6.3.1 Product approvals 373 19.1.6.3.2 Deals 373 19.1.6.4 MnM view 373 19.1.6.4.1 Key strengths 373 19.1.6.4.2 Strategic choices 374 19.1.6.4.3 Weaknesses & competitive threats 374   19.1.7 ILLUMINA, INC. 375 19.1.7.1 Business overview 375 19.1.7.2 Products/Services/Solutions offered 376 19.1.7.3 Recent developments 377 19.1.7.3.1 Product launches & approvals 377 19.1.7.3.2 Deals 377 19.1.8 BIOMÉRIEUX 378 19.1.8.1 Business overview 378 19.1.8.2 Products/Services/Solutions offered 379 19.1.8.3 Recent developments 379 19.1.8.3.1 Deals 379 19.1.9 MYRIAD GENETICS, INC. 380 19.1.9.1 Business overview 380 19.1.9.2 Products/Services/Solutions offered 381 19.1.9.3 Recent developments 382 19.1.9.3.1 Product launches & approvals 382 19.1.9.3.2 Deals 382 19.1.10 SYSMEX CORPORATION 384 19.1.10.1 Business overview 384 19.1.10.2 Products/Services/Solutions offered 385 19.1.10.3 Recent developments 386 19.1.10.3.1 Deals 386 19.1.11 QUEST DIAGNOSTICS 387 19.1.11.1 Business overview 387 19.1.11.2 Products/Services/Solutions offered 388 19.1.11.3 Recent developments 389 19.1.11.3.1 Deals 389 19.1.12 GUARDANT HEALTH 390 19.1.12.1 Business overview 390 19.1.12.2 Products/Services/Solutions offered 391 19.1.12.3 Recent developments 392 19.1.12.3.1 Product launches & approvals 392 19.1.13 ICON PLC 394 19.1.13.1 Business overview 394 19.1.13.2 Products/Services/Solutions offered 395 19.1.14 TEMPUS AI, INC. 396 19.1.14.1 Business overview 396 19.1.14.2 Products/Services/Solutions offered 397 19.1.14.3 Recent developments 397 19.1.14.3.1 Deals 397 19.1.14.3.2 Other developments 397   19.1.15 CARIS LIFE SCIENCES, INC. 398 19.1.15.1 Business overview 398 19.1.15.2 Products/Services/Solutions offered 399 19.1.15.3 Recent developments 400 19.1.15.3.1 Product launches & approvals 400 19.2 OTHER PLAYERS 401 19.2.1 THE ALMAC GROUP 401 19.2.2 AMOY DIAGNOSTICS CO., LTD. 401 19.2.3 ARUP LABORATORIES 402 19.2.4 ABNOVA CORPORATION 402 19.2.5 INVIVOSCRIBE, INC. 403 19.2.6 Q² SOLUTIONS 403 19.2.7 CREATIVE BIOLABS 404 19.2.8 PILLAR BIOSCIENCES 404 19.2.9 ENTROGEN, INC. 405 19.2.10 BIOCARTIS 405 20 RESEARCH METHODOLOGY 406 20.1 RESEARCH DATA 406 20.1.1 SECONDARY DATA 407 20.1.1.1 List of secondary sources 407 20.1.1.2 Key data from secondary sources 408 20.1.2 PRIMARY DATA 408 20.1.2.1 List of primary sources 409 20.1.2.2 Key data from primary sources 409 20.1.2.3 Key industry insights 410 20.1.2.4 Breakdown of primary interviews 411 20.2 MARKET SIZE ESTIMATION 411 20.2.1 TOTAL MARKET SIZE: COMPANION DIAGNOSTICS MARKET 411 20.2.2 BOTTOM-UP APPROACH 411 20.2.2.1 Approach 1: Revenue estimation of key players 412 20.2.2.2 Approach 2: Study of annual reports and investor presentations 412 20.2.2.3 Approach 3: Primary interviews 412 20.2.2.4 Growth forecast 412 20.2.2.5 CAGR projections 413 20.2.3 TOP-DOWN APPROACH 414 20.3 DATA TRIANGULATION 415 20.4 RESEARCH ASSUMPTIONS 415 20.4.1 STUDY-RELATED ASSUMPTIONS 415 20.5 STUDY ASSUMPTIONS 416 20.5.1 PARAMETRIC ASSUMPTIONS 416 20.5.2 GROWTH RATE ASSUMPTIONS 417 20.6 RESEARCH LIMITATIONS 417 20.7 RISK ASSESSMENT 417 21 APPENDIX 418 21.1 DISCUSSION GUIDE 418 21.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 423 21.3 CUSTOMIZATION OPTIONS 425 21.4 RELATED REPORTS 425 21.5 AUTHOR DETAILS 426

TABLE 1 COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 69 TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 71 TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS 72 TABLE 4 EUROPE: MACROECONOMIC INDICATORS 72 TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS 72 TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS 73 TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 73 TABLE 8 COMPANION DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 79 TABLE 9 AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 80 TABLE 10 AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION, 2024–2026 (USD) 81 TABLE 11 AVERAGE SELLING PRICE TREND OF COMPANION DIAGNOSTICS, TECHNOLOGY TYPE, BY REGION, 2024–2026 (USD) 82 TABLE 12 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 83 TABLE 13 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 83 TABLE 14 COMPANION DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 84 TABLE 15 US-ADJUSTED RECIPROCAL TARIFF RATES 87 TABLE 16 KEY PATENTS IN COMPANION DIAGNOSTICS MARKET, 2022–2026 96 TABLE 17 KEY COMPANIES IMPLEMENTING AI IN COMPANION DIAGNOSTICS 99 TABLE 18 CLASSIFICATION OF IVD DEVICES IN EUROPE 101 TABLE 19 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN 103 TABLE 20 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA 104 TABLE 21 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 105 TABLE 22 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106 TABLE 23 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106 TABLE 24 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 106 TABLE 25 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 107 TABLE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%) 111 TABLE 27 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 111 TABLE 28 ADOPTION BARRIERS & INTERNAL CHALLENGES 112 TABLE 29 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 114 TABLE 30 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 117 TABLE 31 ASSAYS, KITS, AND REAGENTS OFFERED BY KEY PLAYERS 119 TABLE 32 COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2024–2031 (USD MILLION) 119 TABLE 33 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 34 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 35 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 36 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 37 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2024–2031 (USD MILLION) 122 TABLE 38 INSTRUMENTS/SYSTEMS OFFERED BY KEY PLAYERS 123 TABLE 39 COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 124 TABLE 40 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 124 TABLE 41 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 42 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 125 TABLE 43 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 44 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS/SYSTEMS, BY REGION, 2024–2031 (USD MILLION) 126 TABLE 45 KEY SOFTWARE & SERVICES AVAILABLE IN MARKET 127 TABLE 46 COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION) 128 TABLE 47 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 48 EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 49 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 129 TABLE 50 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 51 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION) 130 TABLE 52 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 132 TABLE 53 EXAMPLES OF FDA-APPROVED TISSUE-BASED COMPANION DIAGNOSTICS PRODUCTS 133 TABLE 54 COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 55 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 56 EUROPE: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 57 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 58 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 59 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 60 EXAMPLES OF FDA-APPROVED BLOOD-BASED COMPANION DIAGNOSTICS PRODUCTS 137 TABLE 61 COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2024–2031 (USD MILLION) 137 TABLE 62 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 63 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 64 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 65 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 66 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2024–2031 (USD MILLION) 140 TABLE 67 EXAMPLES OF COMPANION DIAGNOSTICS PRODUCTS FOR OTHER SAMPLE TYPES 140 TABLE 68 COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2024–2031 (USD MILLION) 141 TABLE 69 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 70 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 71 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 72 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 73 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2024–2031 (USD MILLION) 143 TABLE 74 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 145 TABLE 75 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION 146 TABLE 76 PCR TESTS/KITS OFFERED BY KEY PLAYERS 147 TABLE 77 COMPANION DIAGNOSTICS MARKET FOR PCR, BY REGION, 2024–2031 (USD MILLION) 147 TABLE 78 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 79 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 80 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 81 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PCR, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 82 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR PCR, BY REGION, 2024–2031 (USD MILLION) 150 TABLE 83 ISH TESTS/KITS OFFERED BY KEY PLAYERS 151 TABLE 84 COMPANION DIAGNOSTICS MARKET FOR ISH, BY REGION, 2024–2031 (USD MILLION) 151 TABLE 85 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 86 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 87 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 88 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ISH, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 89 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR ISH, BY REGION, 2024–2031 (USD MILLION) 154 TABLE 90 NGS TESTS/KITS OFFERED BY KEY PLAYERS 155 TABLE 91 COMPANION DIAGNOSTICS MARKET FOR NGS, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 92 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 93 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 94 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 95 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NGS, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 96 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR NGS, BY REGION, 2024–2031 (USD MILLION) 158 TABLE 97 IHC TESTS/KITS OFFERED BY KEY PLAYERS 159 TABLE 98 COMPANION DIAGNOSTICS MARKET FOR IHC, BY REGION, 2024–2031 (USD MILLION) 159 TABLE 99 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 100 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 101 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 102 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IHC, BY COUNTRY, 2024–2031 (USD MILLION) 161 TABLE 103 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR IHC, BY REGION, 2024–2031 (USD MILLION) 162 TABLE 104 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 163 TABLE 105 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 163 TABLE 106 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 107 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 108 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 109 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2024–2031 (USD MILLION) 165 TABLE 110 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 167 TABLE 111 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2025 VS. 2040 168 TABLE 112 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION) 169 TABLE 113 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 115 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 116 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 117 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2024–2031 (USD MILLION) 171 TABLE 118 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 172 TABLE 119 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 173 TABLE 120 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 121 EUROPE: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 122 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 123 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 124 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2024–2031 (USD MILLION) 175 TABLE 125 BREAST CANCER TESTING PRODUCTS OFFERED BY KEY PLAYERS 176 TABLE 126 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 176 TABLE 127 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 128 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 129 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 130 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 131 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2024–2031 (USD MILLION) 179 TABLE 132 COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY REGION, 2024–2031 (USD MILLION) 180 TABLE 133 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 134 EUROPE: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 135 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 136 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 137 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR LEUKEMIA & LYMPHOMA, BY REGION, 2024–2031 (USD MILLION) 182 TABLE 138 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION) 183 TABLE 139 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 140 EUROPE: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 141 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 142 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2024–2031 (USD MILLION) 185 TABLE 143 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2024–2031 (USD MILLION) 185 TABLE 144 COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY REGION, 2024–2031 (USD MILLION) 186 TABLE 145 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024–2031 (USD MILLION) 186 TABLE 146 EUROPE: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 147 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024–2031 (USD MILLION) 187 TABLE 148 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 149 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR MELANOMA, BY REGION, 2024–2031 (USD MILLION) 188 TABLE 150 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION) 189 TABLE 151 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 152 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 153 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 154 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 155 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2024–2031 (USD MILLION) 191 TABLE 156 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2024–2031 (USD MILLION) 192 TABLE 157 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 158 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 159 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 160 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 161 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2024–2031 (USD MILLION) 194 TABLE 162 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION) 195 TABLE 163 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 164 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 165 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 166 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 167 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2024–2031 (USD MILLION) 197 TABLE 168 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 198 TABLE 169 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 170 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 171 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 172 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 173 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2024–2031 (USD MILLION) 200 TABLE 174 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2031 (USD MILLION) 201 TABLE 175 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 176 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 177 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 178 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 179 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2024–2031 (USD MILLION) 203 TABLE 180 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2024–2031 (NUMBER OF TESTS IN MILLION) 204 TABLE 181 COMPANION DIAGNOSTICS, BY APPLICATION, 2024–2031 (USD MILLION) 206 TABLE 182 COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 207 TABLE 183 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 184 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 185 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 186 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 187 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 209 TABLE 188 COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY REGION, 2024–2031 (USD MILLION) 210 TABLE 189 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 190 EUROPE: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 191 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 192 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 193 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR RESEARCH USE, BY REGION, 2024–2031 (USD MILLION) 212 TABLE 194 COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 214 TABLE 195 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 215 TABLE 196 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 197 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 198 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 199 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 200 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2024–2031 (USD MILLION) 218 TABLE 201 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 219 TABLE 202 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 219 TABLE 203 EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 204 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 205 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 206 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 221 TABLE 207 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 222 TABLE 208 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 209 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 210 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 211 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 212 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 224 TABLE 213 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 225 TABLE 214 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 215 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 226 TABLE 216 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 226 TABLE 217 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 218 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 227 TABLE 219 COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH CDX, 2024–2031 (USD MILLION) 229 TABLE 220 COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 230 TABLE 221 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 230 TABLE 222 EUROPE: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 223 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 231 TABLE 224 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2024–2031 (USD MILLION) 232 TABLE 225 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2024–2031 (USD MILLION) 232 TABLE 226 COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY REGION, 2024–2031 (USD MILLION) 233 TABLE 227 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 233 TABLE 228 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 229 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 234 TABLE 230 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 235 TABLE 231 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2024–2031 (USD MILLION) 235 TABLE 232 COMPANION DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 237 TABLE 233 NORTH AMERICA: MACROECONOMIC INDICATORS 239 TABLE 234 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 239 TABLE 235 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 239 TABLE 236 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 240 TABLE 237 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 240 TABLE 238 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 239 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 241 TABLE 240 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 242 TABLE 241 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 242 TABLE 242 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 242 TABLE 243 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 244 TABLE 244 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 244 TABLE 245 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 244 TABLE 246 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 247 US: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 245 TABLE 248 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 245 TABLE 249 US: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 246 TABLE 250 US: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246 TABLE 251 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 247 TABLE 252 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 247 TABLE 253 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 247 TABLE 254 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 248 TABLE 255 CANADA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 248 TABLE 256 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 249 TABLE 257 CANADA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 249 TABLE 258 CANADA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 249 TABLE 259 EUROPE: MACROECONOMIC INDICATORS 250 TABLE 260 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 250 TABLE 261 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 251 TABLE 262 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 251 TABLE 263 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 251 TABLE 264 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 265 EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 252 TABLE 266 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 252 TABLE 267 EUROPE: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 253 TABLE 268 EUROPE: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 253 TABLE 269 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 254 TABLE 270 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 254 TABLE 271 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 255 TABLE 272 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 273 GERMANY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 256 TABLE 274 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 256 TABLE 275 GERMANY: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 256 TABLE 276 GERMANY: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 257 TABLE 277 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 257 TABLE 278 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 258 TABLE 279 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 258 TABLE 280 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 259 TABLE 281 UK: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 259 TABLE 282 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 259 TABLE 283 UK: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 260 TABLE 284 UK: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 260 TABLE 285 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 261 TABLE 286 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 261 TABLE 287 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 262 TABLE 288 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 289 FRANCE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 263 TABLE 290 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 263 TABLE 291 FRANCE: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 263 TABLE 292 FRANCE: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 264 TABLE 293 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 265 TABLE 294 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 265 TABLE 295 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 265 TABLE 296 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 297 ITALY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 266 TABLE 298 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 267 TABLE 299 ITALY: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 267 TABLE 300 ITALY: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 267 TABLE 301 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 268 TABLE 302 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 268 TABLE 303 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 269 TABLE 304 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 269 TABLE 305 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 270 TABLE 306 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 270 TABLE 307 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 270 TABLE 308 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 271 TABLE 309 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 271 TABLE 310 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 272 TABLE 311 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 272 TABLE 312 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 313 SPAIN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 273 TABLE 314 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 274 TABLE 315 SPAIN: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 274 TABLE 316 SPAIN: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 274 TABLE 317 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 275 TABLE 318 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 276 TABLE 319 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 276 TABLE 320 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 321 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 277 TABLE 322 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 278 TABLE 323 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 278 TABLE 324 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 278 TABLE 325 ASIA PACIFIC: MACROECONOMIC INDICATORS 280 TABLE 326 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 281 TABLE 327 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 281 TABLE 328 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 282 TABLE 329 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 282 TABLE 330 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 331 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 283 TABLE 332 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 283 TABLE 333 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 284 TABLE 334 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 284 TABLE 335 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 285 TABLE 336 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 285 TABLE 337 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 285 TABLE 338 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 286 TABLE 339 CHINA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 286 TABLE 340 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 286 TABLE 341 CHINA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 287 TABLE 342 CHINA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 287 TABLE 343 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 288 TABLE 344 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 288 TABLE 345 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 288 TABLE 346 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 347 JAPAN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 289 TABLE 348 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 290 TABLE 349 JAPAN: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 290 TABLE 350 JAPAN: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 290 TABLE 351 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 291 TABLE 352 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 292 TABLE 353 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 292 TABLE 354 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 355 INDIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 293 TABLE 356 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 293 TABLE 357 INDIA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 294 TABLE 358 INDIA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 294 TABLE 359 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 295 TABLE 360 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 295 TABLE 361 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 295 TABLE 362 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 296 TABLE 363 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 296 TABLE 364 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 296 TABLE 365 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 297 TABLE 366 SOUTH KOREA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 297 TABLE 367 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 298 TABLE 368 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 298 TABLE 369 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 298 TABLE 370 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 371 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 299 TABLE 372 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 299 TABLE 373 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 300 TABLE 374 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 300 TABLE 375 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 301 TABLE 376 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 301 TABLE 377 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 301 TABLE 378 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 379 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 302 TABLE 380 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 303 TABLE 381 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 303 TABLE 382 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 303 TABLE 383 LATIN AMERICA: MACROECONOMIC INDICATORS 304 TABLE 384 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 304 TABLE 385 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 305 TABLE 386 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 305 TABLE 387 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 305 TABLE 388 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 306 TABLE 389 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 306 TABLE 390 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 306 TABLE 391 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 307 TABLE 392 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 307 TABLE 393 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 308 TABLE 394 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 308 TABLE 395 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 308 TABLE 396 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 397 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 309 TABLE 398 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 309 TABLE 399 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 310 TABLE 400 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 310 TABLE 401 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 311 TABLE 402 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 311 TABLE 403 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 311 TABLE 404 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 405 MEXICO: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 312 TABLE 406 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 312 TABLE 407 MEXICO: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 313 TABLE 408 MEXICO: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 313 TABLE 409 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 314 TABLE 410 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 314 TABLE 411 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 314 TABLE 412 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 413 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 315 TABLE 414 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 315 TABLE 415 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 316 TABLE 416 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 316 TABLE 417 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY REGION, 2024–2031 (USD MILLION) 317 TABLE 418 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 317 TABLE 419 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 317 TABLE 420 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 318 TABLE 421 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 422 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 318 TABLE 423 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 319 TABLE 424 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 319 TABLE 425 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 319 TABLE 426 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 320 TABLE 427 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 321 TABLE 428 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 321 TABLE 429 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 322 TABLE 430 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 322 TABLE 431 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 322 TABLE 432 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 323 TABLE 433 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 323 TABLE 434 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 324 TABLE 435 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 324 TABLE 436 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024–2031 (USD MILLION) 324 TABLE 437 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 438 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 325 TABLE 439 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 325 TABLE 440 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY DRUG CLASS ASSOCIATED WITH COMPANION DIAGNOSTICS, 2024–2031 (USD MILLION) 326 TABLE 441 REST OF MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 326 TABLE 442 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN COMPANION DIAGNOSTICS MARKET, JANUARY 2023−MAY 2026 327 TABLE 443 COMPANION DIAGNOSTICS MARKET: DEGREE OF COMPETITION 330 TABLE 444 COMPANION DIAGNOSTICS MARKET: REGION FOOTPRINT 333 TABLE 445 COMPANION DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT 334 TABLE 446 COMPANION DIAGNOSTICS MARKET: INDICATION FOOTPRINT 335 TABLE 447 COMPANION DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT 335 TABLE 448 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 337 TABLE 449 COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 338 TABLE 450 COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 338 TABLE 451 COMPANION DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 341 TABLE 452 COMPANION DIAGNOSTICS MARKET: DEALS, JANUARY 2023–MAY 2026 342 TABLE 453 COMPANION DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2023–MAY 2026 343 TABLE 454 COMPANION DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 343 TABLE 455 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 344 TABLE 456 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 345 TABLE 457 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 347 TABLE 458 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–APRIL 2026 349 TABLE 459 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2023–APRIL 2026 349 TABLE 460 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 351 TABLE 461 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 352 TABLE 462 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 353 TABLE 463 AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2023–APRIL 2026 354 TABLE 464 QIAGEN: COMPANY OVERVIEW 356 TABLE 465 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED 357 TABLE 466 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2023–MAY 2026 358 TABLE 467 QIAGEN: DEALS, JANUARY 2023–MAY 2026 359 TABLE 468 QIAGEN: EXPANSIONS, JANUARY 2023–MAY 2026 359 TABLE 469 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 361 TABLE 470 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 362 TABLE 471 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 364 TABLE 472 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–APRIL 2026 364 TABLE 473 ABBOTT: COMPANY OVERVIEW 366 TABLE 474 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED 367 TABLE 475 ABBOTT: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 368 TABLE 476 ABBOTT: DEALS, JANUARY 2023–APRIL 2026 369 TABLE 477 DANAHER: COMPANY OVERVIEW 371 TABLE 478 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED 372 TABLE 479 DANAHER: PRODUCT APPROVALS, JANUARY 2023–APRIL 2026 373 TABLE 480 DANAHER: DEALS, JANUARY 2023–APRIL 2026 373 TABLE 481 ILLUMINA, INC.: COMPANY OVERVIEW 375 TABLE 482 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 376 TABLE 483 ILLUMINA, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 377 TABLE 484 ILLUMINA, INC.: DEALS, JANUARY 2023–APRIL 2026 377 TABLE 485 BIOMÉRIEUX: COMPANY OVERVIEW 378 TABLE 486 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED 379 TABLE 487 BIOMÉRIEUX: DEALS, JANUARY 2023–APRIL 2026 379 TABLE 488 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 380 TABLE 489 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 381 TABLE 490 MYRIAD GENETICS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–MAY 2026 382 TABLE 491 MYRIAD GENETICS, INC.: DEALS, JANUARY 2023–APRIL 2026 382 TABLE 492 SYSMEX CORPORATION: COMPANY OVERVIEW 384 TABLE 493 SYSMEX CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED 385 TABLE 494 SYSMEX CORPORATION: DEALS, JANUARY 2023-MAY 2026 386 TABLE 495 QUEST DIAGNOSTICS: COMPANY OVERVIEW 387 TABLE 496 QUEST DIAGNOSTICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED 388 TABLE 497 QUEST DIAGNOSTICS: DEALS, JANUARY 2022–DECEMBER 2025 389 TABLE 498 GUARDANT HEALTH: COMPANY OVERVIEW 390 TABLE 499 GUARDANT HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED 391 TABLE 500 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MAY 2026 392 TABLE 501 GUARDANT HEALTH: DEALS, JANUARY 2023-MAY 2026 393 TABLE 502 ICON PLC: COMPANY OVERVIEW 394 TABLE 503 ICON PLC: SERVICES/PRODUCTS/SERVICES/SOLUTIONS OFFERED 395 TABLE 504 TEMPUS AI, INC.: COMPANY OVERVIEW 396 TABLE 505 TEMPUS AI, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 397 TABLE 506 TEMPUS AI, INC.: DEALS, JANUARY 2023–APRIL 2026 397 TABLE 507 TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2023–MAY 2026 397 TABLE 508 CARIS LIFE SCIENCES, INC.: COMPANY OVERVIEW 398 TABLE 509 CARIS LIFE SCIENCES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED 399 TABLE 510 CARIS LIFE SCIENCES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-MAY 2026 400 TABLE 511 COMPANION DIAGNOSTICS MARKET: RISK ASSESSMENT 417 FIGURE 1 COMPANION DIAGNOSTICS MARKET SEGMENTATION 41 FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 45 FIGURE 3 GLOBAL COMPANION DIAGNOSTICS MARKET, 2024–2031 45 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN COMPANION DIAGNOSTICS MARKET, 2023–2025 46 FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF COMPANION DIAGNOSTICS MARKET 47 FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN COMPANION DIAGNOSTICS MARKET, 2025 48 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 49 FIGURE 8 INCREASING ADOPTION OF TARGETED THERAPIES TO DRIVE MARKET 50 FIGURE 9 ASSAYS, KITS, AND REAGENTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 50 FIGURE 10 PCR SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51 FIGURE 11 CANCER SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 51 FIGURE 12 TISSUE SAMPLE SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52 FIGURE 13 MONOCLONAL ANTIBODIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52 FIGURE 14 CLINICAL DIAGNOSTICS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 53 FIGURE 15 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 53 FIGURE 16 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 55 FIGURE 17 COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 68 FIGURE 18 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 75 FIGURE 19 COMPANION DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 76 FIGURE 20 COMPANION DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 79 FIGURE 21 COMPANION DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 85 FIGURE 22 DEALS & FUNDING ACTIVITIES IN COMPANION DIAGNOSTICS MARKET 86 FIGURE 23 PATENT ANALYSIS FOR COMPANION DIAGNOSTICS MARKET, JANUARY 2016–DECEMBER 2025 95 FIGURE 24 MARKET POTENTIAL OF AI IN COMPANION DIAGNOSTICS MARKET 98 FIGURE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 110 FIGURE 26 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 111 FIGURE 27 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT 238 FIGURE 28 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT 280 FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS IN COMPANION DIAGNOSTICS MARKET, 2023–2025 (USD MILLION) 329 FIGURE 30 COMPANION DIAGNOSTICS MARKET SHARE ANALYSIS, 2025 (GLOBAL) 330 FIGURE 31 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 332 FIGURE 32 COMPANION DIAGNOSTICS MARKET: COMPANY FOOTPRINT 333 FIGURE 33 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 337 FIGURE 34 EV/EBITDA OF KEY VENDORS 339 FIGURE 35 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 339 FIGURE 36 COMPANION DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON FOR COMPANION DIAGNOSTICS 340 FIGURE 37 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2025) 345 FIGURE 38 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 352 FIGURE 39 QIAGEN: COMPANY SNAPSHOT (2025) 357 FIGURE 40 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 362 FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2025) 367 FIGURE 42 DANAHER: COMPANY SNAPSHOT (2025) 372 FIGURE 43 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 376 FIGURE 44 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 379 FIGURE 45 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2025) 381 FIGURE 46 SYSMEX CORPORATION: COMPANY SNAPSHOT (2025) 385 FIGURE 47 QUEST DIAGNOSTICS: COMPANY SNAPSHOT (2025) 388 FIGURE 48 GUARDANT HEALTH: COMPANY SNAPSHOT (2025) 391 FIGURE 49 ICON PLC: COMPANY SNAPSHOT (2024) 395 FIGURE 50 TEMPUS AI, INC.: COMPANY SNAPSHOT (2025) 396 FIGURE 51 CARIS LIFE SCIENCES, INC.: COMPANY SNAPSHOT (2025) 399 FIGURE 52 RESEARCH DESIGN 406 FIGURE 53 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 411 FIGURE 54 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2025–2030): IMPACT ON MARKET GROWTH AND CAGR 413 FIGURE 55 TOP-DOWN APPROACH 414 FIGURE 56 DATA TRIANGULATION 415